ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 334

Comparison of Outcomes in Osteoporosis in Patients on Denosumab between Standard and Non-Standard Dosing Intervals

Nouman A. Syed, Mohammed Wiqar, Douglas Einstadter and Marina N. Magrey, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Bone density, Denosumab and osteoporosis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: ARHP Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Denosumab (Dmab) is an antiresorptive agent with an approximate half-life of 26 days and according to the prescribing information the recommended dose is 60 mg subcutaneous every 6 months. Although in real world clinical practice, strict adherence to this dosing regimen is frequently hampered due to delays in prior authorizations, follow up appointment scheduling and missed visits. We hypothesized that patients who did not adhere to the standard dosing regimen would have impaired efficacy of Dmab. The objective of this study is to determine whether there is difference in bone mineral density (BMD) after 2 years of therapy in patients who received Dmab at recommended 6 month intervals as compared with patients who did not.

Methods: All patients between 2009 and 2015 with a primary diagnosis of post-menopausal osteoporosis that had received 4 doses of Dmab in 2 consecutive years were identified from the electronic data base.  Furthermore patients were required to have a baseline DXA within 2 years prior to Dmab initiation and a follow up DXA within 2-3 years thereafter done on the same GE Lunar machine (least significant change for hip 0.036 g/cm2). Patient records were reviewed to obtain information on demographics, weight, smoking history, baseline vitamin D level, Dmab administration and DXA results. Change in BMD at lowest T-score of hip or femoral neck for each patient was used as the outcome measure. Adherence to therapy was defined as receiving subsequent injections at 6 month ± 4 week intervals. Patients were divided into 3 groups with Group 1 being adherent with all injections. Patients in Group 2 were adherent with 2 of 3 subsequent injections whereas Group 3 patients received subsequent injections at 8-12 month intervals and were considered to be non-adherent. Descriptive analysis included continuous variables (means ± SD) and categorical variables (%). Data were compared by using ANOVA.

Results: 50 patients, all females, with mean age of 75 yrs (± 9.4), 74% were Caucasian, 12% African American, 6% Hispanic and 8% were of other ethnicities. 60% smokers and 56% had history of fragility fractures. Mean Vitamin D level was 39.3 ng/ml (± 21.5). The mean lowest BMD at the hip or femoral neck at baseline and follow up were 0.705 g/cm2 (± 0.130) and 0.726 g/cm2 (± 0.130), respectively. 14% of patients were adherent with all 3 injections whereas 40% were categorized as Group 2. 46% were non adherent. The mean change in BMD stratified by groups was 0.035 g/cm2 (± 0.061) for Group 1, 0.006 g/cm2 (± 0.035) for Group 2 and 0.031 g/cm2 (± 0.057) for Group 3. There was no significant difference in mean lowest BMD change at the hip or femoral neck between the 3 groups through ANOVA analysis (p=0.2073).

Conclusion: Despite low adherence to the standard dosing regimen for Dmab there was no significant difference in change of BMD in patients who were not adherent to the current prescribing information.

 


Disclosure: N. A. Syed, None; M. Wiqar, None; D. Einstadter, None; M. N. Magrey, Amgen, AbbVie, and UCB Pharma, 2,UCB and Janssen, 5.

To cite this abstract in AMA style:

Syed NA, Wiqar M, Einstadter D, Magrey MN. Comparison of Outcomes in Osteoporosis in Patients on Denosumab between Standard and Non-Standard Dosing Intervals [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/comparison-of-outcomes-in-osteoporosis-in-patients-on-denosumab-between-standard-and-non-standard-dosing-intervals/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-outcomes-in-osteoporosis-in-patients-on-denosumab-between-standard-and-non-standard-dosing-intervals/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology